Due to the benefits of the FXR-FGF15/19 signaling axis on human health, significant research effort has focused on developing medication to target this axis mainly for liver disease, such as NASH and NAFLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.